308 related articles for article (PubMed ID: 14575824)
1. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience.
Sylvester JE; Blasko JC; Grimm PD; Meier R; Malmgren JA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):944-52. PubMed ID: 14575824
[TBL] [Abstract][Full Text] [Related]
2. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience.
Sylvester JE; Grimm PD; Blasko JC; Millar J; Orio PF; Skoglund S; Galbreath RW; Merrick G
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):57-64. PubMed ID: 17084544
[TBL] [Abstract][Full Text] [Related]
3. Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy.
Lederman GS; Cavanagh W; Albert PS; Israeli R; Lessing J; Savino M; Volpicella F
Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1297-303. PubMed ID: 11286837
[TBL] [Abstract][Full Text] [Related]
4. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
5. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience.
Sylvester JE; Grimm PD; Wong J; Galbreath RW; Merrick G; Blasko JC
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):376-81. PubMed ID: 20864269
[TBL] [Abstract][Full Text] [Related]
6. Role of isotope selection in long-term outcomes in patients with intermediate-risk prostate cancer treated with a combination of external beam radiotherapy and low-dose-rate interstitial brachytherapy.
Wernicke AG; Shamis M; Yan W; Trichter S; Sabbas AM; Goltser Y; Christos PJ; Brennan JS; Parashar B; Nori D
Urology; 2012 May; 79(5):1098-104. PubMed ID: 22546388
[TBL] [Abstract][Full Text] [Related]
7. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses.
Lee LN; Barnswell C; Torre T; Fearn P; Kattan M; Potters L
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):282-9. PubMed ID: 12023131
[TBL] [Abstract][Full Text] [Related]
9. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
Merrick GS; Butler WM; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
[TBL] [Abstract][Full Text] [Related]
10. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
11. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice.
Brachman DG; Thomas T; Hilbe J; Beyer DC
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):111-7. PubMed ID: 10924979
[TBL] [Abstract][Full Text] [Related]
12. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
[TBL] [Abstract][Full Text] [Related]
13. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
[TBL] [Abstract][Full Text] [Related]
14. Isotope selection for patients undergoing prostate brachytherapy.
Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
[TBL] [Abstract][Full Text] [Related]
15. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma.
Ellis RJ; Vertocnik A; Kim E; Zhou H; Young B; Sodee B; Fu P; Beddar S; Colussi V; Spirnak JP; Dinchman KH; Resnick M; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):362-70. PubMed ID: 12957246
[TBL] [Abstract][Full Text] [Related]
16. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation.
Stokes SH
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):129-36. PubMed ID: 10758314
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
Hegde JV; Demanes DJ; Veruttipong D; Raince J; Park SJ; Raman SS; Nickols NG; King CR; Kishan AU; Steinberg ML; Kamrava M
Brachytherapy; 2017; 16(6):1106-1112. PubMed ID: 28807747
[TBL] [Abstract][Full Text] [Related]
18. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
[TBL] [Abstract][Full Text] [Related]
19. Biochemical outcome for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation.
Merrick GS; Butler WM; Lief JH; Galbreath RW; Adamovich E
Cancer J; 2002; 8(4):322-7. PubMed ID: 12184410
[TBL] [Abstract][Full Text] [Related]
20. Palladium-103 brachytherapy for prostate carcinoma.
Blasko JC; Grimm PD; Sylvester JE; Badiozamani KR; Hoak D; Cavanagh W
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):839-50. PubMed ID: 10705004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
